6601-22-5

Basic information

• Product Name: 2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE
• Synonyms: AKOS 90019;2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE;2,4-Dichloro-6-Morpholino-1,3,;2,4-Dichloro-6-(morpholin-4-yl)-1,3,5-triazine;2,6-Dichloro-4-morpholino-1,3,5-triazine;4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine;2,4-Chloro-6-(morpholin-4-yl)-1,3,5-triazine;EOS-60795
• CAS NO: 6601-22-5
• Molecular Formula: C₇H₈Cl₂N₄O
• Molecular Weight: 235.07
• EINECS: 229-544-9
• Mol File: 6601-22-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 137 °C
• Boiling Point: 441.9 °C at 760 mmHg
• Flash Point: 221.1 °C
• Appearance: /
• Density: 1.503 g/cm³
• Vapor Pressure: 5.23E-08mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.01±0.10(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE(6601-22-5)
• EPA Substance Registry System: 2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE(6601-22-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 6601-22-5(Hazardous Substances Data)

Usage

General Description

2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE is a chemical compound that belongs to the family of triazines. It is a white solid that is soluble in organic solvents and is often used as a herbicide in agricultural settings. The compound is known for its ability to selectively kill broadleaf weeds while leaving grasses and cereals unharmed. It works by disrupting the photosynthetic process in plants, leading to their eventual death. However, 2,4-DICHLORO-6-MORPHOLINO-1,3,5-TRIAZINE can also have toxic effects on non-target organisms and the environment, leading to restrictions on its use in some countries. Additionally, it is important to handle and store this chemical with care to minimize potential harm to human health and the environment.

InChI:InChI=1/C7H8Cl2N4O/c8-5-10-6(9)12-7(11-5)13-1-3-14-4-2-13/h1-4H2

Upstream product

• 110-91-8 morpholine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 

Downstream Products

• 331975-73-6 (4-chloro-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-(3-chloro-phenyl)-amine 
• 1454695-06-7 C₂₈H₃₃ClN₈O 
• 1188914-94-4 3-(4-morpholino-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenol 
• 21665-49-6 4-chloro-6-morpholino-N-phenyl-1,3,5-triazin-2-amine 
• 1454695-04-5 C₂₇H₃₁ClN₈O₂ 
• 1454694-93-9 C₂₆H₂₉ClN₈O₂ 
• 1454694-89-3 C₂₅H₂₇ClN₈O₂ 
• 1454695-05-6 C₂₆H₂₈ClFN₈O 
• 1454694-94-0 C₂₅H₂₆ClFN₈O 
• 1454694-90-6 C₂₄H₂₄ClFN₈O 
• 1454694-96-2 C₂₇H₃₁ClN₈O 
• 1454694-91-7 C₂₆H₂₉ClN₈O 
• 1454695-07-8 C₂₆H₂₉ClN₈O 
• 1454694-97-3 C₂₅H₂₇ClN₈O 

Relevant articles and documents

Discovery of ortho-carborane-conjugated triazines as selective topoisomerase I/II inhibitors

The cell growth inhibition profile of 2,4-(2-methyl-ortho-carboranyl)-4- (dimethylamino)-1,3,5-triazine (TAZ-6) was found to be similar to that of ICRF-193, a topoisomerase II inhibitor, as revealed by COMPARE analysis (correlation coefficient (r)≤0.724). Various mono-and di-ortho-carborane- substituted 1,3,5-triazines were synthesized based on the structure of TAZ-6 and tested for their ability to inhibit cell growth and the activities of topoisomerases I and II. Among the compounds synthesized, 3c, 4c, and 4f completely inhibited topoisomerase I activity without affecting topoisomerase II activity, whereas 3a and 3d completely inhibited topoisomerase II activity without affecting topoisomerase I activity, at 100μM.

2-CYANO-1,3,5-TRIAZINE-4,6-DIAMINE DERIVATIVES

The invention relates to the use of a 2-cyano-1,3,5-triazine -4,6-diamine derivative having general formula (I), wherein R1 is (C1-6)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl, aryloxy(C1-4)alkyl, heteroaryl or heteroaryloxy(C1-4)alkyl; R2 is H or (C1-4)alkyl; or R1 and R2 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR5, which ring may be substituted with (C1-4)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl or NR6R7,and which ring may be fused to a benzene ring; R3 is (C1-6)alkyl, (C3-8) cycloalkyl (optionally comprising 1 or more heteroatoms selected from O, S or NR8), aryl, aryl(C1-4)alkyl or heteroaryl; R4 is H or (C1-4)alkyl; or R3 and R4 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR9; R5, R8 and R9 are independently H, (C1-4)alkyl, (C3-8) cycloalkyl, aryl or aryl(C1-4)alkyl; R6 and R7 are independently H or (C1-4)alkyl; or R6 and R7 form together with the nitrogen to which they are bound a 4-8 membered heterocyclic ring; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of osteoporosis and atherosclerosis.